Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9849823, 8 pages
https://doi.org/10.1155/2017/9849823
Research Article

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients

1Department of Infectious Diseases, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, China
2Guangdong Provincial Key Laboratory of Liver Disease, Guangdong, China

Correspondence should be addressed to Qingxian Cai; moc.361@000002xqc and Yutian Chong; moc.621@yzykgnohcty

Received 5 April 2017; Revised 31 May 2017; Accepted 10 July 2017; Published 15 October 2017

Academic Editor: Aparup Das

Copyright © 2017 Zhanyi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Gower, C. C. Estes, S. Hindman, K. Razavi-Shearer, and H. Razavi, “Global epidemiology and genotype distribution of the hepatitis C virus,” Journal of Hepatology, supplement 1, pp. S45–S57, 2014. View at Publisher · View at Google Scholar
  2. WH Organization, “Guidelines for the screening , care and treatment of persons with hepatitis C infection,” 2014.
  3. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “eginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–I67, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-M. Pawlotsky, S. Chevaliez, and J. G. McHutchison, “The hepatitis C virus life cycle as a target for new antiviral therapies,” Gastroenterology, vol. 132, no. 5, pp. 1979–1998, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Soriano, E. Vispo, E. Poveda et al., “Directly acting antivirals against hepatitis C virus,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 8, Article ID dkr215, pp. 1673–1686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Lawitz, F. F. Poordad, P. S. Pang et al., “Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial,” The Lancet, vol. 383, no. 9916, pp. 515–523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. L. M. Hagan, M. S. Sulkowski, and R. F. Schinazi, “Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals,” Hepatology, vol. 60, no. 1, pp. 37–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Vierling, M. Davis, S. Flamm et al., “Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response,” Journal of Hepatology, vol. 60, no. 4, pp. 748–756, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. AASLD/IDSA HCV Guidance Panel, “Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus,” Hepatology, vol. 62, no. 3, pp. 932–954, 2015. View at Publisher · View at Google Scholar
  10. European Association for the Study of the Liver, “EASL recommendations on treatment of Hepatitis C 2015,” Journal of Hepatology, vol. 63, no. 1, pp. 199–236, 2015. View at Publisher · View at Google Scholar
  11. S. Zeuzem, “Clinical implications of hepatitis C viral kinetics,” Journal of Hepatology, vol. 31, no. 1, pp. 61–64, 1999. View at Google Scholar · View at Scopus
  12. P. Halfon and C. Sarrazin, “Future treatment of chronic hepatitis C with direct acting antivirals: Is resistance important?” Liver International, vol. 32, no. 1, pp. 79–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. J. Bartels, J. C. Sullivan, E. Z. Zhang et al., “Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment,” Journal of Virology, vol. 87, no. 3, pp. 1544–1553, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Dietz, S. Susser, C. Berkowski, D. Perner, S. Zeuzem, and C. Sarrazin, “Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients,” PLoS ONE, vol. 10, no. 8, article e0134395, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. A. M. Lam, C. Espiritu, S. Bansal et al., “Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA,” Journal of Virology, vol. 85, no. 23, pp. 12334–12342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. I.-H. Shih, I. Vliegen, B. Peng et al., “Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 4196–4203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Tanaka, F. Katayama, H. Kato et al., “Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures,” Journal of Epidemiology, vol. 21, no. 6, pp. 401–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Rong, R. Xu, H. Xiong et al., “Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004–2007 and 2008–2011,” Archives of Virology, vol. 159, no. 12, pp. 3231–3237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Fu, Y. Wang, W. Xia et al., “New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors,” Journal of Viral Hepatitis, vol. 18, no. 1, pp. 42–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Chenna, H. Sugawara, T. Koike et al., “Multiple sequence alignment with the Clustal series of programs,” Nucleic Acids Research, vol. 31, no. 13, pp. 3497–3500, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. D. B. Smith, J. Bukh, C. Kuiken et al., “Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource,” Hepatology, vol. 59, no. 1, pp. 318–327, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Tamura, J. Dudley, M. Nei, and S. Kumar, “MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0,” Molecular Biology and Evolution, vol. 24, no. 8, pp. 1596–1599, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Hézode, N. Forestier, G. Dusheiko et al., “Telaprevir and peginterferon with or without ribavirin for chronic HCV infection,” The New England Journal of Medicine, vol. 360, no. 18, pp. 1839–1850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Guedj, P. S. Pang, J. Denning et al., “Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938,” Antiviral Therapy, vol. 19, no. 2, pp. 211–220, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Kuntzen, J. Timm, A. Berical et al., “Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients,” Hepatology, vol. 48, no. 6, pp. 1769–1778, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Howe, J. Long, S. Black et al., “Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3/4A-protease variants on the efficacy of boceprevir combined with peginterferon/ribavirin,” Open Forum Infectious Diseases, vol. 1, no. 2, 2014. View at Publisher · View at Google Scholar
  27. S. Gaudieri, A. Rauch, K. Pfafferott et al., “Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy,” Hepatology, vol. 49, no. 4, pp. 1069–1082, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Lenz, T. Verbinnen, B. Fevery et al., “Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies,” Journal of Hepatology, vol. 62, no. 5, pp. 1008–1014, 2015. View at Publisher · View at Google Scholar
  29. S. Vallet, F. Viron, C. Henquell et al., “NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1–5,” Antiviral Therapy, vol. 16, no. 7, pp. 1093–1102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Sarrazin, H. Dvory-Sobol, E. S. Svarovskaia, B. Doehle, J. F. McCarville, and P. S. Pang, “Baseline and post-baseline resistance analyses of phase 2/3 studies of ledipasvir/sofosbuvir +/- RBV,” Hepatology, vol. 60, article 1128a, 2014. View at Google Scholar
  31. Z. Plaza, V. Soriano, E. Vispo et al., “Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor,” Antiviral Therapy, vol. 17, no. 5, pp. 921–926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Hernandez, N. Zhou, J. Ueland, A. Monikowski, and F. McPhee, “Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors,” Journal of Clinical Virology, vol. 57, no. 1, pp. 13–18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Paolucci, L. Fiorina, B. Mariani et al., “Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients,” Virology Journal, vol. 10, article 355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. V. C. Di Maio, V. Cento, C. Mirabelli et al., “Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 5, pp. 2781–2797, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Poveda, D. L. Wyles, Á. Mena, J. D. Pedreira, Á. Castro-Iglesias, and E. Cachay, “Update on hepatitis C virus resistance to direct-acting antiviral agents,” Antiviral Research, vol. 108, pp. 181–191, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Manns, S. Pol, I. M. Jacobson, P. Marcellin, S. C. Gordon, C. Y. Peng et al., “All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study,” The Lancet, vol. 384, no. 9954, pp. 1576–1605, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. O. Lenz, L. Vijgen, J. M. Berke et al., “Virologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202),” Journal of Hepatology, vol. 58, no. 3, pp. 445–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. Z.-W. Chen, H. Li, H. Ren, and P. Hu, “Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data,” Scientific Reports, vol. 6, Article ID 20310, 2016. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Zeuzem, C. Hézode, J.-P. Bronowicki et al., “Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection,” Journal of Hepatology, vol. 64, no. 2, pp. 292–300, 2016. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Gao, “Antiviral activity and resistance of HCV NS5A replication complex inhibitors,” Current Opinion in Virology, vol. 3, no. 5, pp. 514–520, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Á. Patiño-Galindo, K. Salvatierra, F. González-Candelas, and F. X. López-Labrador, “Comprehensive screening for naturally occurring hepatitis c virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 4, pp. 2402–2416, 2016. View at Publisher · View at Google Scholar · View at Scopus